2011
DOI: 10.1016/j.ymeth.2011.07.001
|View full text |Cite
|
Sign up to set email alerts
|

Internal radiotherapy of painful bone metastases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
13
0
1

Year Published

2014
2014
2022
2022

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 29 publications
(15 citation statements)
references
References 193 publications
(370 reference statements)
1
13
0
1
Order By: Relevance
“…153 Sm-EDTMP showed a pain relief rate in 62–84% of patients with metastatic bone pain. These studies are also summarized in reviews [ 6 8 ]. Meanwhile, in a study of comparison between the effects of the 89 SrCl 2 and 153 Sm-EDTMP to patients with bone metastases, there was no statistical difference in response rates [ 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…153 Sm-EDTMP showed a pain relief rate in 62–84% of patients with metastatic bone pain. These studies are also summarized in reviews [ 6 8 ]. Meanwhile, in a study of comparison between the effects of the 89 SrCl 2 and 153 Sm-EDTMP to patients with bone metastases, there was no statistical difference in response rates [ 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…Despite numerous studies attempting to better understand bone metastasis pathophysiology, there are as yet no established and efficient clinical methods for their cure and/or their prevention. Currently, medical management of bone metastases is based on local approaches (i.e., surgery, radiation therapy) or systemic strategies such as molecular targeted therapies [ 66 , 69 ].…”
Section: Bone Metastasis Treatmentsmentioning
confidence: 99%
“…Currently, in many Nuclear Medicine centres in addition to radioiodine therapy for thyroid cancer, radionuclide therapies such as radioembolisation of liver tumours and radiopeptide- and radioimmunotherapies for neuroendocrine tumours and lymphomas, as well as treatment of painful bone metastases with different radionuclides, are being performed [ 1 5 ]. Most importantly, radioligand therapy for metastatic prostate cancer with Lu-177-PSMA, which has been established in some centres, shows remarkable treatment response and prolongation of overall survival in patients who do not have any other treatment options [ 6 10 ]; this further demonstrates the increasing importance of our specialty.…”
Section: Dear Editormentioning
confidence: 99%